Insider Transactions Reported by 21 Insiders of X4 Pharmaceuticals, Inc

Symbol: XFOR on Nasdaq
Location: Boston, MA

Key facts

XFOR - X4 Pharmaceuticals, Inc has 21 insiders with reported activity on this page.
Net insider value flow over the last year: +$177,177.
Recent transaction rows are available for direct filing-level review.

Change

Buy value: $249,997; sell value: $72,820.
Net share flow: +69,245.

Research use

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to buying over the last 12 months. Net value: +$177,177.

Buys

$249,997

Shares: 86,206

Insiders: 1

Sells

$72,820

Shares: 16,961

Insiders: 1

Net

+$177,177

Shares: +69,245

Insiders: 0

Window (months)	Buy shares	Sell shares	Buy $	Sell $	Net $
0-3	0	16,961	$0	$72,820	-$72,820
3-6	0	0	$0	$0	$0
6-9	86,206	0	$249,997	$0	+$249,997
9-12	0	0	$0	$0	$0

X4 Pharmaceuticals, Inc executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Paula Ragan	President and CEO, Director	$1,515,173			Mixed	12 Feb 2025
Adam R. Craig	Executive Chairman, Director	$1,090,652	+$249,997	+30%	Filing P/S	29 Oct 2025
David Kirske	Chief Financial Officer	$756,896	-$72,820	-8.8%	Filing P/S	12 May 2026
John Volpone	President	$550,773			Mixed	29 Oct 2025
Mary DiBiase	Chief Operating Officer	$518,005			Mixed	12 Feb 2025
Christophe Arbet-Engels	Chief Medical Officer	$392,350			Mixed	12 Feb 2025
Adam S. Mostafa	Chief Financial Officer	$385,900			Mixed	12 Feb 2025
Arthur Taveras	Chief Scientific Officer	$218,459			Filing P/S	04 Oct 2024
Derek M. Meisner	Chief Legal Officer	$130,640			Mixed	17 Aug 2022
Diego Cadavid	Chief Medical Officer	$93,696			Mixed	01 Mar 2022
William Aliski	Director	$85,241			Mixed	10 Jun 2024
Alison Frances Lawton	Director	$85,241			Mixed	10 Jun 2024
Mark Baldry	Chief Commercial Officer	$62,886			Mixed	16 May 2025
Natasha Fay Thoren	Chief Legal Officer	$1,797			Market	20 May 2025
Murray Stewart	Director	$1,497			Market	01 Jan 2026
Keith Woods	Director	$1,140			Market	09 Jun 2025
Michael S. Wyzga	Director	$1,055			Market	01 Jan 2026
Gary Bridger	Director	$897			Market	01 Jan 2026
David W. J. Mcgirr	Director	$897			Market	09 Jun 2025
Francoise de Craecker	Director	$897			Market	01 Jan 2026
Rene Russo	Director				Mixed	02 Jun 2021

Top shareholders of X4 Pharmaceuticals, Inc (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
MORGAN STANLEY	13F 13D/G	Company	10% from 13D/G	9,466,992	$39,098,676	—	31 Mar 2026	13F 13D/G
Empery Asset Management, LP	13F 13D/G	Company	10% from 13D/G	8,944,118	$36,939,207	—	31 Mar 2026	13F 13D/G
Deep Track Capital, LP	13F 13D/G	Company	10% from 13D/G	6,339,535	$26,182,280	—	31 Mar 2026	13F 13D/G
Coastlands Capital LP	13D/G	—	10%	2,491,638	$7,773,911	+$37,418	03 Oct 2025	13D/G
FMR LLC	13D/G 13F	Company	9.7%	8,499,100	$33,996,400	$0	31 Oct 2025	13D/G 13F
Saturn V Capital Management LP	13F 13D/G	Company	7.4% from 13D/G	6,456,646	$26,665,948	—	31 Mar 2026	13F 13D/G
PERCEPTIVE ADVISORS LLC	13F 13D/G	Company	7.3% from 13D/G	6,737,648	$27,826,486	—	31 Mar 2026	13F 13D/G
Growth Equity Opportunities 18 VGE, LLC	13D/G	—	6.2%	5,057,610	$17,496,802	+$9,734,867	27 Oct 2025	13D/G
Trails Edge Capital Partners, LP	13D/G 13F	Company	5.8%	5,227,222	$20,333,894	+$11,320,168	31 Dec 2025	13D/G 13F
VANGUARD GROUP INC	13D/G	The Vanguard Group	4.8%	8,200,903	$1,558,172	$0	31 Dec 2024	13D/G
BIOTECHNOLOGY VALUE FUND L P	13D/G	BVF PARTNERS L P/IL	3.9%	3,411,993	$13,272,653	+$4,544,819	31 Dec 2025	13D/G
BlackRock, Inc.	13F 13D/G	Company	3% from 13D/G	1,211,794	$5,004,710	—	31 Mar 2026	13F 13D/G
Nantahala Capital Management, LLC	13F 13D/G	Company	2.8% from 13D/G	2,449,468	$10,116,303	—	31 Mar 2026	13F 13D/G
ORBIMED ADVISORS LLC	13D/G	—	1.7%	134,947	$25,640	$0	30 Jun 2025	13D/G
Mark Baldry	3/4/5	Chief Commercial Officer	0.03%	25,337	$62,886	—	16 May 2025	3/4/5
Natasha Fay Thoren	3/4/5	Chief Legal Officer	0.01%	9,462	$1,797	—	20 May 2025	3/4/5
Murray Stewart	3/4/5	Director	0.01%	7,883	$1,497	—	01 Jan 2026	3/4/5
Keith Woods	3/4/5	Director	0.01%	6,000	$1,140	—	09 Jun 2025	3/4/5
Michael S. Wyzga	3/4/5	Director	0.01%	5,555	$1,055	—	01 Jan 2026	3/4/5
David W. J. Mcgirr	3/4/5	Director	0.01%	4,722	$897	—	09 Jun 2025	3/4/5
Francoise de Craecker	3/4/5	Director	0.01%	4,722	$897	—	01 Jan 2026	3/4/5
Gary Bridger	3/4/5	Director	0.01%	4,722	$897	—	01 Jan 2026	3/4/5
Bain Capital Life Sciences Investors, LLC	13F	Company	9.1%	7,967,454	$32,905,585	—	31 Mar 2026	13F
Kalehua Capital Management LLC	13F	Company	4.3%	3,722,840	$15,375,329	—	31 Mar 2026	13F
VANGUARD CAPITAL MANAGEMENT LLC	13F	Company	4%	3,497,612	$14,445,138	—	31 Mar 2026	13F
BRAIDWELL LP	13F	Company	3.8%	3,272,954	$13,517,300	—	31 Mar 2026	13F
Rosalind Advisors, Inc.	13F	Company	3.7%	3,214,766	$13,276,984	—	31 Mar 2026	13F
NEA Management Company, LLC	13F	Company	3.4%	3,233,743	$13,355,359	—	31 Mar 2026	13F
Blackstone Inc.	13F	Company	3.1%	2,681,922	$11,076,338	—	31 Mar 2026	13F
BVF INC/IL	13F	Company	2.6%	2,233,742	$9,225,354	—	31 Mar 2026	13F
Samsara BioCapital, LLC	13F	Company	2.1%	1,832,566	$7,568,498	—	31 Mar 2026	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	1.4%	1,210,514	$4,999,423	—	31 Mar 2026	13F
Woodline Partners LP	13F	Company	1.1%	1,001,095	$4,134,522	—	31 Mar 2026	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.1%	939,726	$3,883,286	—	31 Mar 2026	13F
GOLDMAN SACHS GROUP INC	13F	Company	1%	882,134	$3,643,213	—	31 Mar 2026	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.98%	856,222	$3,536,197	—	31 Mar 2026	13F
STEMPOINT CAPITAL LP	13F	Company	0.98%	850,742	$3,513,564	—	31 Mar 2026	13F
VANGUARD FIDUCIARY TRUST CO	13F	Company	0.55%	480,733	$1,985,427	—	31 Mar 2026	13F
STATE STREET CORP	13F	Company	0.46%	403,534	$1,666,595	—	31 Mar 2026	13F
MARSHALL WACE, LLP	13F	Company	0.39%	336,834	$1,391,123	—	31 Mar 2026	13F
Stonepine Capital Management, LLC	13F	Company	0.38%	335,309	$1,384,826	—	31 Mar 2026	13F
Venrock Adviser, LLC	13F	Company	0.38%	330,525	$1,365,068	—	31 Mar 2026	13F
UBS Group AG	13F	Company	0.31%	267,340	$1,104,114	—	31 Mar 2026	13F
Qube Research & Technologies Ltd	13F	Company	0.25%	218,954	$904,280	—	31 Mar 2026	13F
ACORN CAPITAL ADVISORS, LLC	13F	Company	0.25%	234,039	$966,583	—	31 Mar 2026	13F
NORTHERN TRUST CORP	13F	Company	0.2%	178,235	$736,111	—	31 Mar 2026	13F
Pale Fire Capital SE	13F	Company	0.19%	167,590	$692,147	—	31 Mar 2026	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.17%	150,676	$622,292	—	31 Mar 2026	13F
Affinity Asset Advisors, LLC	13F	Company	0.17%	145,000	$598,850	—	31 Mar 2026	13F
Palumbo Wealth Management LLC	13F	Company	0.15%	131,014	$541,088	—	31 Mar 2026	13F

Recent Insider Transactions by Companies or Individuals for X4 Pharmaceuticals, Inc

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
David Kirske	XFOR	Common Stock	Sale	-8.78%	$72,820	$4.29	-16,961	176,293	12 May 2026	Direct
Gary Bridger	XFOR	Stock Option (right to buy)	Award				110,000	0	01 Jan 2026	Direct
Francoise de Craecker	XFOR	Stock Option (right to buy)	Award				110,000	0	01 Jan 2026	Direct
Michael S. Wyzga	XFOR	Stock Option (right to buy)	Award				110,000	0	01 Jan 2026	Direct
Murray Stewart	XFOR	Stock Option (right to buy)	Award				110,000	0	01 Jan 2026	Direct
Adam R. Craig	XFOR	Stock Option (right to buy)	Award				2,329,154	2,329,154	29 Oct 2025	Direct
John Volpone	XFOR	Stock Option (right to buy)	Award				2,329,154	2,329,154	29 Oct 2025	Direct
David Kirske	XFOR	Stock Option (right to buy)	Award				1,552,769	1,552,769	29 Oct 2025	Direct
Adam R. Craig	XFOR	Common Stock	Purchase	29.7%	$249,997	$2.90	86,206	376,087	23 Oct 2025	Direct
John Volpone	XFOR	Common Stock	Award				289,881	289,881	14 Aug 2025	Direct
John Volpone	XFOR	Stock Option (right to buy)	Award				529,201	529,201	14 Aug 2025	Direct
Adam R. Craig	XFOR	Common Stock	Award				289,881	289,881	14 Aug 2025	Direct
Adam R. Craig	XFOR	Stock Option (right to buy)	Award				529,201	529,201	14 Aug 2025	Direct
David Kirske	XFOR	Common Stock	Award				193,254	193,254	14 Aug 2025	Direct
David Kirske	XFOR	Stock Option (right to buy)	Award				352,800	352,800	14 Aug 2025	Direct
John Volpone	XFOR	Stock Option (right to buy)	Award				1,609,873	1,609,873	12 Aug 2025	Direct
Adam R. Craig	XFOR	Stock Option (right to buy)	Award				1,609,873	1,609,873	12 Aug 2025	Direct
David Kirske	XFOR	Stock Option (right to buy)	Award				1,073,249	1,073,249	12 Aug 2025	Direct
Murray Stewart	XFOR	Common Stock	Award	23.5%			1,500	7,883	09 Jun 2025	Direct
Francoise de Craecker	XFOR	Common Stock	Award	46.6%			1,500	4,722	09 Jun 2025	Direct
Gary Bridger	XFOR	Common Stock	Award	46.6%			1,500	4,722	09 Jun 2025	Direct
Keith Woods	XFOR	Common Stock	Award	33.3%			1,500	6,000	09 Jun 2025	Direct
David W. J. Mcgirr	XFOR	Common Stock	Award	46.6%			1,500	4,722	09 Jun 2025	Direct
Michael S. Wyzga	XFOR	Common Stock	Award	37%			1,500	5,555	09 Jun 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.